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Evidence for anticipation in Beckwith–Wiedemann
syndrome
Siren Berland1, Mia Appelba¨ck1,2, Ove Bruland1, Jasmin Beygo3, Karin Buiting3, Deborah JG Mackay4,5,6,
I Karen Temple4,5,6 and Gunnar Houge*,1,2
Classical Beckwith–Wiedemann syndrome (BWS) was diagnosed in two sisters and their male cousin. The children’s mothers
and a third sister were tall statured (178, 185 and 187 cm) and one had mild BWS features as a child. Their parents had
average heights of 173 cm (mother) and 180 cm (father). This second generation tall stature and third generation BWS
correlated with increased methylation of the maternal H19/IGF2-locus. The results were obtained by bisulphite treatment and
subclone Sanger sequencing or next generation sequencing to quantitate the degree of CpG-methylation on three locations: the
H19 promoter region and two CTCF binding sites in the H19 imprinting control region (ICR1), specifically in ICR1 repeats B1
and B7. Upon ICR1 copy number analysis and sequencing, the same maternal point variant NCBI36:11:g.1979595T4C that
had been described previously as a cause of BWS in three brothers, was found. As expected, this point variant was on the
paternal allele in the non-affected grandmother. This nucleotide variant has been shown to affect OCTamer-binding transcription
factor-4 (OCT4) binding, which may be necessary for maintaining the unmethylated state of the maternal allele. Our data
extend these findings by showing that the OCT4 binding site mutation caused incomplete switching from paternal to maternal
ICR1 methylation imprint, and that upon further maternal transmission, methylation of the incompletely demethylated variant
ICR1 allele was further increased. This suggests that maternal and paternal ICR1 alleles are treated differentially in the female
germline, and only the paternal allele appears to be capable of demethylation.
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INTRODUCTION
Beckwith–Wiedemann syndrome (BWS, OMIM no. 130650) is an
overgrowth condition caused by epigenetic or genetic alterations in
the imprinted H19/IGF2-KCNQ1/CDKN1C locus, spanning nearly
1 Mb in 11p15.5.1 The two major causes of BWS are increased IGF2
expression or decreased CDKN1C expression. The growth inhibitor
CDKN1C is normally expressed from the maternal chromosome 11.
On the paternal chromosome, inhibition of CDKN1C is associated
with the expression of a long noncoding RNA called KCNQ1OT1 or
LIT1 antisense to KCNQ1, the potassium channel gene involved in
long-QT-syndrome type 1 and Jervell/Lange-Nielsen syndrome. In
contrast, the growth factor IGF2 gene is expressed from the paternal
chromosome only. On the maternal chromosome, the noncoding
RNA gene H19 is expressed instead. The choices between H19 or IGF2
expression, and LIT1 or CDKN1C expression, are regulated
epigenetically. IGF2 expression is associated with methylation of the
insulator (CTCF) binding sites between H19 and IGF2, also called
imprinting centre region 1 (ICR1), and CDKN1C expression is
associated with methylation of the LIT1 promoter, also called
imprinting centre region 2 (ICR2).
The regulation of 11p15.5 imprinting that causes monoallelic
paternal IGF2 expression and monoallelic maternal CDKN1C expres-
sion is complex, which also explains why there are many different
molecular causes of BWS.2 The most common cause is reduced
expression of CDKN1C, which is usually due to sporadically occurring
reduction in maternal ICR2 methylation (B50% of BWS cases), but
sometimes associated with maternal CDKN1C mutations (5–10%).
The second most common cause is IGF2 overexpression, usually due
to paternal uniparental disomy of 11p (B20% of BWS cases), but
also to inappropriate ICR1 methylation on the maternal allele, which
inhibits H19 and stimulates IGF2 expression (B5%).1 In the latter
situation, small deletions or mutations in the ICR1 that are likely to
disrupt the insulator function of the region have been observed with a
high sibling recurrence risk.3–8 Recently, it was found that such small
and overlapping deletions of ICR1 had variable effects on methylation
of the maternal ICR1, indicating that maintenance of maternal
hypomethylation was partly dependent on the spatial arrangement
of the CTCF binding sites.8
Here, we describe a family with a previously reported ICR1 single
nucleotide variant (NCBI36:11:g.1979595T4C) in an OCTamer-
binding transcription factor-4 (OCT4) binding site and a gradual
increase in ICR1 methylation over the next two generations, the first
generation being tall statured, the second generation having full-BWS
phenotype with Wilms tumours. This family indicates that ICR1
mutations may affect the ability to establish a maternal ICR1
methylation pattern of the paternal allele in female gonads, that is,
1Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway; 2Department of Clinical medicine, University of Bergen, Bergen, Norway;
3Institut fu¨r Humangenetik, Universita¨tsklinikum Essen, Essen, Germany; 4Faculty of Medicine, University of Southampton, Southampton, UK; 5Wessex Genetics Service,
Southampton University Hospitals Trust, Southampton, UK; 6Salisbury Hospital NHS Foundation Trust, Salisbury, UK
*Correspondence: Professor G Houge, Center for Medical Genetics and Molecular Medicine Haukeland University Hospital, Jonas Liesvei N-5021, Bergen, Norway.
Tel: +47 55 97 54 44; Fax: +47 55 97 54 78; E-mail: gunnar.houge@helse-bergen.no
Received 3 October 2012; revised 2 March 2013; accepted 12 March 2013
European Journal of Human Genetics (2013), 1–5
& 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13
www.nature.com/ejhg
to demethylate the paternal ICR1 region. Our data also indicate that
the maternal and paternal ICR1 alleles are treated differently in the
maternal gonads, that is, that the maternal alleles are not demethy-
lated (if methylated) in the maternal germ line, and may later be
subject to a passive (stochastic) increase in methylation. To the best of
our knowledge, this is the first description of anticipation in an
epigenetic syndrome.
PATIENTS AND METHODS
Family
BWS was diagnosed in two sisters (III-1 and III-2) and their male cousin (III-3,
see Figure 1). Elective caesarean section was performed in both sisters due to
large babies. Both sisters had classical BWS features including Wilms tumour
and visceromegaly. III-1 was born in week 38 with macroglossia and large
kidneys, birth weight was 4860 g (860 g497.5th centile), length 53 cm (97.5th
centile). As an infant, she was successfully treated for Wilms tumour with
chemotherapy. At age 6 years, an operative tongue reduction was performed.
III-2 was born at term with macroglossia and large kidneys, birth weight 5280 g
(880 g497.5th centile). At age 9 months, she was nephrectomised due to Wilms
tumour in her right kidney and mild nephroblastomatosis in her left kidney
was also detected. The sisters are now 10 and 13 years, and both have good
school performances and growth parameters in upper percentiles (III-1 97.5th
centile and III-2 95th centile). Their male cousin (III-3, DZ twin) died from
medical complications after a caesarean section in week 29. There was marked
polyhydramnios. Birth weight was 2130 g (330 g497.5th centile), length 44 cm,
head circumference 28 cm and he had visceromegaly (especially of the kidneys),
macroglossia and general subcutaneous oedema. In comparison, his healthy
unaffected DZ sister III-4 was 1170 g (5th centile), 38 cm and had the same
head circumference at birth. None of the three affected children had neonatal
hypoglycaemia, were markedly asymmetric or had transverse creases on their
ear helices. The children’s two mothers and the mothers’ sister were tall
statured (178, 185 and 187 cm, that is, lengths from the 96th centile and above)
with large hands, and at least one had mild BWS features (large tongue,
protruding stomach) as a child (II-1 in Figure 1). The sisters’ parents had
heights of 173 cm (mother, 85th centile) and 180 cm (father, 75th centile), and
none of them had any BWS-like features as infants. II-1 was born at term with
a large tongue and birth weight 5 kg (0.4 kg497.5th centile). II-3 and II-4 are
DZ twins born in week 31 with birth weights 1800 g (50th centile) and 2350 g
(99th centile), respectively, and II-4 also had a large tongue. All sisters have very
mild and asymptomatic scoliosis, no hemihyperplasia and normally sized
tongues as adults.
Methylation specific multiplex ligation-dependent probe
amplification (MS-MLPA) analysis and bisulphite treatment
followed by subclone sequencing
Blood DNA samples were obtained from all individuals except III-1 and III-2,
where only saliva DNA samples could be obtained. MS-MLPA copy number
and methylation analysis of the BWS/Silver-Russell syndrome region on
chromosome 11 was done in the routine diagnostic laboratory using the
SALSA MLPA ME030 kit version C2 (MRC-Holland, Amsterdam) and
following the manufacturer’s instructions. We also obtained saliva DNA
samples from II-1 and II-4 to compare with the results of MS-MLPA analysis
of blood DNA, and similar levels of methylation was found: 0.7 in saliva DNA
from both individuals, compared with 0.71 and 0.75 in their blood DNA
(Figure 1). The bisulphite conversion of DNA was performed with Applied
Biosystems methylSEQr Bisulphite Conversion Kit (Life Technologies, Carlsbad,
CA, USA), according to the manufacturer’s protocol. PCR was performed
using primers designed by Methyl Primer Express Software v1.0 (Applied
Biosystems, Life Technologies) for bisulphite sequencing-specific PCR. Forward
primer: 50-ATTATTTTGGTTTTTGGTGAGG-30 (unconverted: 50-ACCACCT
TGGCCTTTGGTGAGG-30); reverse primer: 50-ATACCATAAAAATTCCCC-
CATA-30 (unconverted: 50-ATGCCATGGAAATTCCCCCATG-30) (HG19: chr11:
2019867-2020153). M13 tails were added to all the primers as part of our
routine to obtain uniform PCR conditions. PCR was performed in a 25ml
reaction containing 1x AmpliTaq Gold 360 Master Mix Forward (Invitrogen, Life
Technologies, Carlsbad, CA, USA), 16% 360 CG enhancer (Invitrogen, Life
Technologies), 10mM forward primer and 10mM reverse primer. The PCR
conditions were as follows: denaturation at 95 1C for 5 min, 5 cycles of 95 1C for
30 s, 50 1C for 2 min and 72 1C for 3 min, followed by 35 cycles of 95 1C for 30 s,
58 1C for 1 min and 72 1C for 3 min, and finally a hold at 60 1C for 60 min. The
PCR products were then cloned using TOPO TA Cloning Kit for Sequencing
(Invitrogen, Life Technologies), following the manufacturer’s instructions. Ten
clones were purified using QIAprep Spin Miniprep kit (Qiagen, Hilden,
Germany) and sequenced by Sanger sequencing using the BigDye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems, Life Technologies, Calrsbad, CA,
USA) with T3 or T7 primers. Clean up was performed using the using Big DyeX
Terminator purification (Applied Biosystems, Life Technologies). The sequences
were resolved on a 3730 Genetic Analyser (Applied Biosystems, Life Technol-
ogies) and analysed with QUMA (Riken, Japan). To calculate the average
methylation level in controls (n¼ 5, including the grandmother of the family)
and affected (n¼ 3 per generation, see Figure 1), the average of all measurements
per sample was first calculated, and thereafter the mean per group (Table 1). For
MS-MLPA, four repeated measurements per sample were done, and for
bisulphite sequencing, seven informative positions with differential methylation
were measured once per patient (see Supplementary Table 1 and Supplementary
Figure 1 with legend for details). Five data points were noninformative because
they were highly methylated in all samples with no difference between patients
and controls (Supplementary Table 1), and these data points were therefore
excluded. The individual MS-MLPA and bisulphite data can also be seen in
Figure 1, and mean data with 95% confidence intervals can be found in Table 1.
Bisulphite treatment followed by next generation sequencing
Bisulphite treatment was conducted using the EZ DNA Methylation-Gold Kit
(Zymo Research Europe, Freiberg, Germany) according to the manufacturer’s
manual. For each individual bisulphite amplicon libraries were generated and
sample-specific barcode sequences were added. The amplicons were purified,
diluted and clonally amplified in an emulsion PCR before sequencing on the
I 
II 
III
1 2
1 2 3 4 5 
1 2 3 4 
0.46/0.49/0.53 0.49/0.45/0.54  
0.71/0.71/0.81  0.60/0.87/0.63   0.75/0.71/0.74  
1.06/0.90/0.84  0.82/0.82/0.73   0.67/0.86/0.85  
Figure 1 Family pedigree. The degree of methylation of the locus between
H19 and ICR1 was investigated by routine MLPA testing and bisulphite
subclone sequencing, indicated by the (first ratio/) and (/middle ratio/),
respectively. The methylation of the CTCF binding site 6 (CTS6) within the
B1 repeat was investigated by bisulphite next generation sequencing,
indicated by the (/final ratio) below the pedigree symbols.
Table 1 Mean degree of ICR1 methylation in the first, second and
third generations with 95% confidence intervals (parentheses)
MLPA-test Bisulphite sequencing
1. generation (n¼2) 0.48 (0.45–0.51) 0.47 (0.39–0.55)
2. generation (n¼3) 0.71 (0.66–0.76) 0.75 (0.72–0.78)
3. generation (n¼3) 0.84 (0.81–0.87) 0.86 (0.81–0.91)
Abbreviations: ICR1, imprinting control region; MLPA, multiplex ligation-dependent probe
amplification.
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Roche/454 GS junior system was carried out. For subsequent data analysis the
Geneious software (Biomatters, Auckland, New Zealand) and BiqAnalyzer HT
were used.9 A detailed description has been published elsewhere.8 A minimum
of 1058 reads for each sample was obtained. The average conversion rate was
99.0% for CTS1 and 99.1% for CTS6.
ICR1 sequencing
After confirmation of complete 11p15 grandmaternal haplotype segregation
with large growth/BWS (Supplementary Figure 2), ICR1 and the H19 proximal
promoter (HG19:chr11:2,020,402-2,024,682) were sequenced by standard meth-
ods from a product of 4281 bp generated using primers 50-TGCACATACTTTG
CACATGG/CGCTGTGGCTGATGTGTAG-30, as described;3 further details are
available on request. To determine the parental origin of the sequence variant,
200 ng genomic DNA was cleaved using restriction enzyme McrBc (New England
Biolabs, Ipswich, MA, USA) following the manufacturer’s instructions; then DNA
was desalted and concentrated using Amicon 30K microconcentrator columns
(Millipore, Billerica, MA, USA) before amplification using primers 50-CAACACA
AGGATCCTAGACC/TCTTCGTATCGGGCCATATC-30 and Sanger sequencing.
RESULTS
Our family shows dominant inheritance of BWS with a clinical
picture that is compatible with anticipation (Figure 1). This impres-
sion was in line with the results of the routine MS-MLPA methylation
testing of the BWS locus, which showed an increase in ICR1
methylation from normal level (0.49) in the grandmother to B0.71
in the second generation with tall stature and B0.84 in the third
generation (Table 1, Supplementary Table 1), in the three children
with classical BWS (Figure 1). These data were reproduced by
bisulphite treatment and subclone sequencing to measure the degree
of CpG-methylation of the H19 differentially methylated promotor
region (Figure 2).
To investigate whether the same tendency could be found in the
CTCF binding sites (called CTS and numbered from 1 to 7) of the
ICR1 repeats (Figure 2), the degree of methylation of two such sites
was investigated by highly quantitative next generation bisulphite
sequencing: CTS6 in B-type repeat B1, on the H19-side of ICR1, and
CTS1 in B-type repeat B7, on the IGF2-side of ICR1 (Figure 2).
Although CTS1 was fully methylated already in the grandmother’s
children (II-1, II-3 and II-4; Supplementary Table 1), CTS6 showed
the same tendency towards increased methylation from generation II
to III. In the mothers of generation II, the average degree of
methylation was 73%, and in their children, the average degree of
methylation was 81% (Figure 1). It thus seems that CTS1 was more
prone to acquire methylation than CTS6.8 To further illustrate the
molecular correlation to the observed clinical anticipation,
methylation heat maps of the degree of CTS1 and CTS6
methylation from the grandmother to daughters to grandchildren
are shown in Figure 3. Of note, the degree of methylation in CTS6
correlates well with the clinical severity (Figure 3), that is, the number
of BWS symptoms and findings (see above; II-3oII-4oII-1 and III-
2oIII-1oIII-3). All normal individuals had heat map plots showing
average (B50%) methylation (Supplementary Figure 3).
As dominant BWS can be associated with mutations in ICR1,
between the H19 noncoding RNA gene and the growth factor gene
IGF2, this region was examined for mutations or deletions. Long-
range PCR did not detect any microdeletions in ICR1 that could
explain imprinting disturbances. However, ICR1 sequencing revealed
the same maternal point variant NCBI36:11:g.1979595T4C
(NCBI37:11:g.2023019T4C, see Figure 2) that had been described
previously as a cause of BWS in three brothers.10 To determine the
parental origin of the variant, genomic DNA was digested with the
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Figure 2 Illustration of the H19/IGF2 ICR1. Above the line approximate positions of CTCF binding sites are marked with green dots, and OCT4 sites are
marked with blue dots. The position of a CpG island in the H19 promoter is shown above the line. Below the line the differentially methylated CpG sites
investigated by the routine MLPA kit are marked with red dots, and these sites are not included in the segment from the CpG island (marked as ‘PCR
product’) that was investigated by bisulphite treatment followed by subclone sequencing and that contained seven differentially methylated CpG sites. The
position of the common B1.8kb microdeletion4 associated with BWS is marked with a red bar, and the OCT4 binding site mutation is also shown, as well
as the sequencing result of II-3 before and after McrBc digestion of methylated DNA. Please note that the g.2023019A4G mutation corresponds to the
T4C mutation on the antisense strand, which was described by10. The position of CTCF binding sites (CTS) in ICR1 are shown, and of these CTS6 and
CTS1 were investigated by next generation bisulphite sequencing.
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methylation-sensitive restriction enzyme McrBC, which digests
methylcytosine-containing DNA, and then amplified and sequenced.
In the digested DNA from II-1 and II-3, the variant became
apparently homozygous (II-3 result shown in Figure 2), indicating
that it was present on the partially unmethylated, and therefore
maternally inherited allele. In I-2, the non-affected grandmother,
the opposite was found, indicating that the point variant was
on the grandmother’s paternal allele. Haplotype and sequencing
information showed that the three sisters in generation II and the
three affected children in generation III inherited this point variant,
but not by the unaffected DZ sibling in generation III (Supplementary
Figure 2).
DISCUSSION
From a clinical point of view, the second generation tall stature and
third generation BWS in our family suggested anticipation (Figure 1).
Alternatively, the increased clinical severity might be a random result
of variable expression, not uncommon in BWS (see e.g. Scott et al.11).
However, the increasing degree of methylation from the unaffected
carrier grandmother of a paternal ICR1 variant over the two
subsequent generations gave a molecular correlate to the observed
anticipation (Figures 1 and 3, Table 1). The increased degree of ICR1
methylation was found both on routine MLPA-based methylation
testing and bisulphite subclone sequencing of the CpG island region
in the H19 promoter, and bisulphite next generation sequencing of
the CTCF binding site in the B1 repeat region of ICR1 (CTS6), but
not the more IGF2-proximal CTCF binding site in the B7 repeat
(CTS1) (Figures 2 and 3). Upon ICR1 sequencing to find a cause of
the apparent anticipation, a previously found variant affecting OCT4
binding was found (Figure 2).10 It was highly unlikely that this
represented a founder mutation as the other family was French and
the Norwegian family had no known French roots. Nevertheless, to
exclude that this could be a founder mutation, Christine Gicquel was
most helpful and sent us the SNP information of the ICR1 locus in
their family, and when compared to our family, a common haplotype
was excluded. We could therefore conclude that the same
NCBI37:11:g.2323019T4C (NCBI36:11:1979595T4C) variant had
occurred on two different genetic backgrounds.
Recently, a family with another variant reducing OCT4 binding was
described.3 This variant 1979624A4C was 31 nt centomeric to the
1979595T4C variant found by Demars et al.10 and us. Of note, in
this family there were two affected brothers with prolonged post
pubertal growth and final heights above the 99th centiles (204 cm and
208 cm, respectively), which is atypical for BWS patients. They also
had renal problems, one had cysts and the other had a Wilms tumour,
and neither was markedly asymmetric. This suggests that there may
be clinical features that distinguish ICR1 mutation patients from
other patients with BWS. None of the reported patients had the
characteristic ear creases and growth did not decelerate in their teens,
resulting in final statures above the 97.5th centile. If the latter also will
hold true for the third generation in our family is yet unknown, as
they are all children. Nevertheless, if a child with BWS and ICR1
hypermethylation has a tall statured mother, this should alert to the
possibility of dominant inheritance, especially if the child also has
Wilms tumour. Absence of ear creases should strengthen this
suspicion.
It has previously been shown that the T4C variant in the ICR
region affects OCT4/SOX2 binding,10 and our data can be interpreted
to imply that the variant interferes with gonadal switching from
paternal to maternal imprinting. The same may be true for the A4C
variant reported by Poole et al.3 In the latter case, however, classical
BWS occurred already in the first generation. One explanation for this
discrepancy could be that the A4C variant is more detrimental to
OCT4 binding than the T4C variant. Alternatively, the cause could
be random variability in clinical expression. Our family suggests,
however, that true anticipation as an explanation for increased clinical
Figure 3 DNA methylation analysis: Heat maps of the methylation patterns
obtained by next generation bisulphite sequencing of two CTCF binding
sites: CTS1 and CTS6. The heat maps are ordered from left to right by the
degree of methylation, and this also corresponds to the clinical severity.
Only data from individuals harbouring the allele with the OCT4 binding site
mutation is shown. The pedigree marks below the panels are the same as in
Figure 1. Lines represent sequence reads, columns CpGs. Blue –
unmethylated – maternal (mat); red – methylated – paternal (pat); white –
missing sequence information.
Figure 4 The imprinting status of the grand-grand-paternal allele after
grandmaternal and maternal transmissions. The OCT4 binding site mutation
apparently causes incomplete demethylation upon grandmaternal
transmission (A), and further methylation upon maternal transmission (B).
Of note, further demethylation, as in A, was not seen in B (marked by
the X), suggesting that only paternal alleles can be demethylated in the
maternal gonads. Blue¼methylated (paternal pattern) and
red¼ unmethylated (maternal pattern).
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severity may take place in BWS. This is supported by a recent report
on the consequences of ICR1 microdeletions, where at least two of the
six families had features compatible with anticipation, described as ‘a
kind of epigenetic memory effect’ by the authors.8 Possibly, the
phenomenon of anticipation in BWS is not limited to OCT4 binding
site mutations, but could be an explanation for non-penetrance in
ICR1 deletion families as well. This has implications for genetic
counselling of BWS families with ICR1 deletions or mutations.
Transmission through the male germline implies a potential BWS
risk not necessarily in the next, but in subsequent generations if the
mutation is passed through the female germline. Second, transmission
of the mutation through the maternal germline may first give rise to
BWS in later (third and fourth) generations if the mutation is ‘mild’.
From a more fundamental biological perspective, our findings give
clues to how gonadal imprinting switching is regulated. The grand-
mother inherited a fully methylated paternal allele containing the
T4C variant from her father, and a normal demethylated maternal
allele from her mother. In the next generation, her three daughters
inherited the grandpaternal ICR1 allele (with the T4C variant) and
they had methylation levels of around 73%. This implies either that
the grandpaternal allele was incompletely demethylated in their
mother’s gonads or that the variant allele was completely demethy-
lated in the germline, but had reduced resistance to subsequent
postzygotic remethylation. There are experimental data to support
both of these suggestions.12 A recent study showed that interference
with OCT4 binding in P19 embryonic carcinoma cells rendered the
H19 allele partially resistant to demethylation, but also that when
partially methylated, further methylation seeding (remethylation)
could easily take place.13 Methylation seeding implies that
inappropriate methyl groups recruit binding proteins that directly
and indirectly promote both histone compaction and further DNA
methylation. Moreover, on a more general genomic scale it has been
shown that maintenance of imprinting marks in early zygotic
development requires not only protection against postfertilisation
demethylation, but also protection against somatic remethylation.14 A
similar requirement for OCT4/SOX2-binding elements to maintain
the maternal demethylated state has been found in the Prader-Willi/
Angelman syndrome imprinting centre.15
To explain anticipation, reduced protection against somatic remethy-
lation is not enough. There must also be an element of demethylation
resistance in the germline. However, even if the mutation caused only
partial ICR1 demethylation to take place in the female germline
(grandmother and daughters), one would still expect less ICR1
methylation in third generation (the children with BWS), not more.
This remains true even if a susceptibility to somatic remethylation
should vary somewhat from individual to individual. Of note, the
grandpaternal (normal) allele inherited by III-4 (also confirmed by
haplotyping, see Supplementary Figure 2) was completely demethylated
in the same maternal gonad that could not demethylate the grand-
maternal allele (II-4 in Figure 1). This indicates that mutations
interfering with OCT4 binding may have different effects in paternal
and maternal inheritance. Apparently, unlike the paternal allele, the
maternal allele is incapable of being actively demethylated in the
maternal germline—otherwise there would have been no anticipation.
Our hypothesis on differential handling of paternal and maternal alleles
in the maternal gonads is illustrated in Figure 4.
In conclusion, we have both clinical and molecular evidence for the
occurrence of anticipation in rare cases of BWS, and our data also
indicate that only paternally inherited H19/IGF2 loci are demethy-
lated in the maternal germline.
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